Clinical Trial: New Monoclonal Antibody for Relapsed Multiple Myeloma (Lintuzumab + Actinium-225)
Clinical Trial: Phase 1 BCMA-CD3 Bispecific Antibody for Relapsed/Refractory Myeloma Patients
Changing Our Approach to Myeloma Care Changes Outcomes
Elotuzumab, Pomalyst and Dex Show Decreased Risk of Progression in Multiple Myeloma
Summer Is Officially Here… What’s the Best Way to Protect Yourself?
Stem Cell Transplant Still Improves Myeloma Patient Survival
EHA: INSIGHT Update on Multiple Myeloma
Raynaud's Disease and Myeloma… How to Cope
SparkCures Founder Brian McMahon Named One of "40 Under 40 in Cancer"
Legend Biotech and Janssen Partner on CAR T Cell Treatment for Multiple Myeloma
Overcoming Proteasome Inhibitor Resistance, Muhamed Baljevic, MD, University of Nebraska
Dr. Baljevic shares a clinical trial using cabozantinib with carfilzomib for patients who have become refractory (resistant) to carfilzomib.
Daratumumab with PD-1 Inhibitor Study Discontinued for Multiple Myeloma
Clinical Trials and Compassionate Use in Multiple Myeloma
Introducing HealthTree for Multiple Myeloma Patients with Rafael Fonseca, MD, Mayo Clinic Scottsdale
Dr. Rafael Fonseca joins Myeloma Crowd Radio to share a new tool for myeloma patients called HealthTree.
Donate Vitamin Bottles to TerraCycle, Raise Money for the Myeloma Crowd
Understanding the Mutations that Cause Multiple Myeloma May Help Drive Personalized Treatment
How Fast Your Multiple Myeloma Responds To Treatment May be Linked to Survival
Clinical Trials: What are Bispecific Antibodies?
New York Round Table - May 5, 2018
Blood Biopsies vs Bone Marrow Biopsies – The Good News For The Week …
Antibody-Drug Conjugates and Multiple Myeloma
MCRT Review: St Louis, Missouri – March 10, 2018
Only Your Genes Will Tell
Patient Power: How Can Myeloma Patients Combat Neuropathy?
